Miragen
Miragen Therapeutics, Signal Genetics Complete Merger, New Financing Round
Privately held Miragen will pick up Signal's Nasdaq listing, and the combined company is scheduled to begin trading today.
Miragen Therapeutics, Signal Genetics Agree to Merge
The combined company will be focused on Miragen's microRNA therapeutics programs, following the divestiture of Signal's molecular diagnostic assets.
Despite an initial focus on cardiovascular disease, Miragen has moved programs in hematological cancer and fibrosis to the front of its pipeline.
NEW YORK (GenomeWeb) – Miragen Therapeutics this week announced that its research and development collaboration with France's Servier has been extended by two years to October 2016.
Voyager Therapeutics, a startup developing adeno-associated viral vector therapies, including RNAi-based ones, for central nervous system disorders, has named Dinah Sah as its senior vice president of neuroscience.
Nov 14, 2013
May 23, 2013
Mar 7, 2013
Jan 10, 2013
Dec 20, 2012
Oct 25, 2012
Apr 26, 2012
Jan 12, 2012
Nov 10, 2011
Oct 20, 2011
Aug 25, 2011
Jul 28, 2011
Jul 7, 2011
Jun 23, 2011
May 26, 2011
Jan 27, 2011